🇺🇸 FDA
Patent

US 10617663

Dosage forms and therapeutic uses of L-4-chlorokynurenine

granted A61KA61K31/198A61K9/0053

Quick answer

US patent 10617663 (Dosage forms and therapeutic uses of L-4-chlorokynurenine) held by VISTAGEN THERAPUETICS, INC. expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VISTAGEN THERAPUETICS, INC.
Grant date
Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/198, A61K9/0053, A61P, A61P25/14